Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 7/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 7/20 | 0.37 |
| ▸ | IKBKB | O14920 | 5/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2200291 | 0.80 | CDC7 (0.42) | CDC7BRD4IKBKBJAK2JAK3 | |
| SCHEMBL2198824 | 0.79 | CDC7 (0.59) | CDC7BRD4IKBKBJAK2JAK3 | |
| SCHEMBL2200262 | 0.79 | CDC7 (0.45) | CDC7BRD4IKBKBJAK2JAK3 | |
| SCHEMBL4343305 | 0.79 | IKBKB (0.41) | CDC7BRD4IKBKB | |
| SCHEMBL2199810 | 0.75 | CDC7 (0.56) | CDC7BRD4IKBKBJAK2JAK3 | |
| SCHEMBL2199605 | 0.74 | PARP1 (0.47) | CDC7BRD4ALKIKBKBJAK2 | |
| SCHEMBL2200000 | 0.74 | IKBKB (0.51) | CDC7BRD4IKBKBJAK2JAK3 | |
| SCHEMBL3195667 | 0.73 | KIF11 (0.32) | — | |
| SCHEMBL2200146 | 0.73 | BRD4 (0.62) | CDC7BRD4IKBKBJAK2JAK3 | |
| SCHEMBL2200754 | 0.73 | BRD4 (0.49) | CDC7BRD4IKBKBJAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977371-B2 | Pyrrole derivative having ureido group and aminocarbonyl group as substituents | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20100099675-A1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDO GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099675-A1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDO GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | UACA, IL6, IL6ST | CDC7 4329/4885BRD4 497/4885ALK 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.